ライフサイエンスコーパス: intratumoral

1 reduced tumor growth in vivo, with increased intratumoral 5hmC.

2 ic activation of the LXR pathway reduced the intratumoral abundance of regulatory T cells (Treg) and

3 F(ab)(2)-mediated GPVI inhibition increased intratumoral accumulation of coadministered chemotherape

4 cells suppresses tumor growth by increasing intratumoral accumulation of effector CD8(+) T cells and

5 of the chemokine receptors that mediate the intratumoral accumulation of immune cells.

6 vasiveness, which may be associated with the intratumoral accumulation of infiltrated B cells.

7 We found that early intratumoral accumulation of interferon gamma (IFN-gamma

8 Intratumoral adeno-associated virus delivery of CRISPRa

9 In this study, we describe that the intratumoral administration of 41BB agonistic Abs led to

10 Intratumoral administration of potent therapies utilizes

11 Our results indicate that intratumoral administration of these recombinant NDVs, p

12 period of time (> 1 month) following direct intratumoral administration.

13 4 treatment with combinatorial effects after intratumoral administration.

14 y membrane permeable, restricting its use to intratumoral administration.

15 Intratumoral adrenergic nerves release noradrenaline to

16 cancer models, we discover that significant intratumoral and intertumoral genomic heterogeneity evol

17 in women and is a complex disease with high intratumoral and intertumoral heterogeneity.

18 Decreasing the intratumoral androgen biosynthesis by using an inhibitor

19 ografts express high levels of AR and retain intratumoral androgen concentrations similar to tumors g

20 To perform longitudinal characterization of intratumoral angiogenesis and oxygenation by using dynam

21 e find that >70% of HNSCC lesions respond to intratumoral anti-CTLA-4.

22 In intratumoral areas, fSHG and bSHG (forward-SHG and backw

23 Using intratumoral B cells and plasma cells, we generated seve

24 a cells but the antigen specificity of these intratumoral B cells is not well understood(1-8).

25 et al. indicate that chemokines produced by intratumoral Batf3 dendritic cells are critical for effe

26 The synergism is attributed to the effective intratumoral buildup of PAL/HCQ, which otherwise exhibit

27 Here, we show that the intratumoral burst release of the protein annexin A5 fro

28 djuvanted seasonal influenza vaccination via intratumoral, but not intramuscular, injection converts

29 nse was facilitated by CXCL9 production from intratumoral CD103(+) dendritic cells, suggesting that C

30 As tumors grew, the distribution of intratumoral CD11b(+) cells became more heterogeneous.

31 RF4 as specifically expressed by a subset of intratumoral CD4+ effector Tregs with superior suppressi

32 concept of systemic antitumor activity after intratumoral CD40 triggering with ISF35 in combination w

33 Single-cell RNA sequencing of RNA from intratumoral CD45(+) cells showed that CD11b(+) cells in

34 als a shared regulatory program that governs intratumoral CD8(+) T cell exhaustion and CD4(+) T folli

35 CXCL9 axis is required for reinvigoration of intratumoral CD8(+) T cell responses in response to PD-1

36 With these changes in the Treg population, intratumoral CD8(+) T cells acquired a more functional p

37 to explore the dynamics and distribution of intratumoral CD8(+) T cells and CD11b(+) myeloid cells i

38 RXDX-106 proportionally increased intratumoral CD8(+) T cells and T-cell function as indic

39 RNA sequencing on the intratumoral CD8(+) T cells identified the presence of T

40 phase II, is a promising monitoring tool for intratumoral CD8(+) T cells in patients treated with can

41 Treatment-induced changes in intratumoral CD8(+) T cells may represent a biomarker to

42 aled a high sensitivity for the detection of intratumoral CD8(+) T-cell infiltrates upon either singl

43 d" CAF to a quiescent phenotype and promoted intratumoral CD8(+) T-cell infiltration, overcoming the

44 tumor-bearing humanized mice correlated with intratumoral CD8(+) T-cell infiltration.

45 approximately 10% of CRC patients, with high intratumoral CD8+ T cell infiltration, but poor prognosi

46 following radiation and successfully drives intratumoral cDC1 maturation, ultimately resulting in du

47 radiation therapy promotes the activation of intratumoral cDC1s in radioimmunogenic murine tumors, an

48 melanoma patients with low T(reg) abundance, intratumoral cDC2 density alone correlates with abundant

49 ession in invasive tumor cells compared with intratumoral cells.

50 f epigenetic enzymes may be used to decrease intratumoral cellular heterogeneity and treatment resist

51 resent work demonstrates a novel concept for intratumoral chemo-radio combination therapy for locally

52 idated the efficacy of PEG-PLA/CWO/PTX-based intratumoral chemo-radio therapy in mouse tumor xenograf

53 ptional propensity to metastasize early into intratumoral, chemokine-secreting nerves.

54 The present study proposes how intratumoral chemoradiation can be best implemented.

55 Intratumoral chemotherapy has the potential to address t

56 beta-catenin and E-cadherin in CK5+ but not intratumoral CK5- cells and single-cell RNA sequencing f

57 ter analysis and minimal spanning tree using intratumoral collagen parameters allowed the identificat

58 Adaptive therapy seeks to exploit intratumoral competition to avoid, or at least delay, th

59 ng implants (ISFIs) allow for a high initial intratumoral concentration and sustained release of the

60 Here we show that intratumoral copper levels influence PD-L1 expression in

61 functionally parallel the activity of their intratumoral counterparts.

62 hich recruited, antigen-loaded and activated intratumoral, cross-presenting dendritic cells (DCs).

63 substantiate that recruiting and activating intratumoral, cross-priming DCs is achievable and critic

64 d humans, chronic imatinib therapy decreases intratumoral DCs and effector CD8(+) T cells.

65 SCLC tumor cells were permissive to MYXV and intratumoral delivery into patient-derived xenografts re

66 Previously, we demonstrated that intratumoral delivery of adenoviral vector encoding sing

67 Intratumoral delivery of cisplatin by endobronchial ultr

68 ing releasable transporters (CART) for local intratumoral delivery of mRNA coding for costimulatory a

69 Here we show that microparticle-mediated intratumoral delivery of NAMPT inhibitor GMX1778 induces

70 The intratumoral delivery of rNDVs expressing immunotherapeu

71 avidity T cells have sustained contacts with intratumoral dendritic cells and tumor targets compared

72 olid stress within tumors contribute to poor intratumoral distribution of nanomedicine.

73 f an unconjugated antibody could improve the intratumoral distribution of the antibody-dye conjugate

74 rontal lobe tumors and treated with a single intratumoral dose of surfen demonstrated reduced tumor b

75 re was a 3-fold increase in normalized total intratumoral Dox intensity with the Dox + Val ISFIs comp

76 n of LDH inhibitors resulted in the greatest intratumoral drug accumulation, inducing tumor cell deat

77 ug eluting depot allowing for a high initial intratumoral drug concentration.

78 The intratumoral drug concentrations calculated for 4 refere

79 SN22 prodrug delivery resulted in sustained intratumoral drug concentrations, dramatically higher th

80 environment and transport considerations for intratumoral drug delivery.

81 n from the tumor/boundary interface and poor intratumoral drug retention.

82 gative interaction, decreasing the number of intratumoral effector T cells.

83 Analysis of the intratumoral epigenome revealed increased 5hmC with AA t

84 Retrospective data suggest that intratumoral ERCC1 levels may determine platinum sensiti

85 d by patient-specific mathematical models of intratumoral evolutionary dynamics.

86 actors stimulating myofibroblasts, promoting intratumoral fibrosis and supporting tumour growth.

87 ity to PD-1 blockade and that augmenting the intratumoral function of this chemokine system could imp

88 tigen-specific CD8+ T cells, as well as oHSV intratumoral gene activity.

89 Intratumoral generation of ADO depends on the sequential

90 romosomal DNA (ecDNA) amplification promotes intratumoral genetic heterogeneity and accelerated tumor

91 Intratumoral genetic heterogeneity, germline mutations,

92 , we identified numerous samples with marked intratumoral genetic heterogeneity, including branching

93 instability contributes to the phenomenon of intratumoral genetic heterogeneity, provides the genetic

94 Intratumoral genomic heterogeneity in glioblastoma (GBM)

95 The consumption of intratumoral glucose by GOD leads to the in situ elevati

96 Intratumoral glutathione peroxidase 4 overexpression or

97 del depends on Kit inhibition, which reduces intratumoral GM-CSF, leading to the accumulation of Batf

98 roach could support stratifying patients for intratumoral GSL expression to identify an optimal thera

99 lts: We identified 3 phenotypically distinct intratumoral habitats: metabolically active and heteroge

100 ments to avoid platelet clearance, increases intratumoral hemorrhage and concomitant tumor cell apopt

101 vessels highly permeable and caused massive intratumoral hemorrhage.

102 The impact of intratumoral heterogeneity (ITH) and the resultant neoan

103 Additionally, intratumoral heterogeneity and adaptations to therapeuti

104 and anatomic locations to investigate their intratumoral heterogeneity and developmental origins.

105 ty with demonstrated ability in highlighting intratumoral heterogeneity and identifying small lesions

106 ur understanding of mechanisms that regulate intratumoral heterogeneity and our ability to modulate i

107 including known breast cancer biomarkers of intratumoral heterogeneity and the co-localization of tu

108 To accommodate for potential intratumoral heterogeneity and tumors of mixed subtypes,

109 , we report that MAPK signaling shows strong intratumoral heterogeneity and unexpectedly remains regu

110 elanoma, the frequencies of intertumoral and intratumoral heterogeneity are controversial.

111 The extent of spatial and temporal intratumoral heterogeneity as medulloblastoma metastasiz

112 Intratumoral heterogeneity can occur via phenotype trans

113 While intratumoral heterogeneity has been extensively studied

114 Intratumoral heterogeneity in bladder cancer is a barrie

115 Our understanding of intratumoral heterogeneity in cancer continues to evolve

116 oximity was found to in part account for the intratumoral heterogeneity in EGFR activity observed.

117 We also identified a degree of intratumoral heterogeneity in immune markers in bladder

118 on biopsies, which is consistent with marked intratumoral heterogeneity in MET CNG observed in early-

119 Intratumoral heterogeneity is a common feature of many m

120 ochastic nature of genetic alterations, this intratumoral heterogeneity is often viewed as chaotic.

121 onstrated the intercancer, interpatient, and intratumoral heterogeneity of interacting immune checkpo

122 The intertumoral and intratumoral heterogeneity of lung cancers as well as in

123 itive NSCLC across 59 sectors to investigate intratumoral heterogeneity of MET CNG.

124 Both intertumoral and intratumoral heterogeneity of the hyperpolarized pyruvat

125 We observed inter- and intratumoral heterogeneity of uptake, and (89)Zr-bevaciz

126 tion histopathologic analysis suggested that intratumoral heterogeneity or sample damage prior to PIR

127 gland typing provided an additional layer of intratumoral heterogeneity that was associated with diff

128 yzable tumors showed an ITGAV expression and intratumoral heterogeneity was low.

129 Clinical relapse depends upon intratumoral heterogeneity which serves as substrate var

130 rovided by mRNA expression through resolving intratumoral heterogeneity with enhancer cell-type speci

131 iomarkers and therapeutics, intertumoral and intratumoral heterogeneity, and current and emerging tar

132 olic dysregulation, heightened angiogenesis, intratumoral heterogeneity, and deleterious tumor microe

133 xtensive subclonal diversification, elevated intratumoral heterogeneity, and dismal disease outcome.

134 ide a mechanistic link between antigenicity, intratumoral heterogeneity, and immune suppression acros

135 However, in the setting of significant intratumoral heterogeneity, biopsies may not be represen

136 udies illustrate the importance of analyzing intratumoral heterogeneity, changes in population dynami

137 derstanding of how such events contribute to intratumoral heterogeneity, dynamic subpopulations, and

138 Cellular plasticity contributes to intratumoral heterogeneity, metastatic spread, and treat

139 k of prominent T cell infiltrates, extensive intratumoral heterogeneity, poor patient survival and a

140 blastoma tumors exhibit extensive inter- and intratumoral heterogeneity, which has contributed to the

141 shaped by the microenvironment and leads to intratumoral heterogeneity, which is characterized by di

142 Intratumoral heterogeneity, which is manifested in almos

143 sis mechanism, resulting in intertumoral and intratumoral heterogeneity.

144 d-/third-line TKIs but shows high inter- and intratumoral heterogeneity.

145 load, cancer-testis antigen expression, and intratumoral heterogeneity.

146 le therapeutic strategies that consider SCLC intratumoral heterogeneity.

147 ically dynamic nature of the tumor cells and intratumoral heterogeneity.

148 nderstood, with significant intertumoral and intratumoral heterogeneity.

149 ling tumors to adapt while maintaining their intratumoral heterogeneity.

150 e in overcoming therapy resistance caused by intratumoral heterogeneity.

151 Intratumoral heterogeneity; presence of a robust, reacti

152 We also revealed that intratumoral HLA-II presentation was dominated by profes

153 A novel biosensor is used to detect intratumoral hydrogen peroxide, allowing real-time monit

154 ve strategy to counteract the development of intratumoral hypoxia and the accumulation of CSCs.

155 ular circuitries involved in the presence of intratumoral hypoxia and the augmented population of CSC

156 have shown that pharmacological induction of intratumoral hypoxia caused an unexpected rise in tumor

157 Intratumoral hypoxia causes the formation of dysfunction

158 The intratumoral hypoxia gene-signature is a better prognost

159 xpression patterns in cells that experienced intratumoral hypoxia in vivo compared to cells exposed t

160 Intratumoral hypoxia occurs in 90% of solid tumors and i

161 Solid tumors are characterized by intratumoral hypoxia, and hypoxic cells are associated w

162 B16F10 melanoma showed 5.5-fold increase in intratumoral IL-2 and 2.1-fold increase in infiltrating

163 bicarbonate during TACE increased peri- and intratumoral immune cell infiltration (P = .002).

164 the need for a tumor priming step to improve intratumoral immune cell infiltration.

165 ingle-cell transcriptome analysis of >50,000 intratumoral immune cells after therapy treatment showed

166 An extensive infiltrate of intratumoral immune cells is a hallmark of classic Hodgk

167 is new qNPA technology is useful to quantify intratumoral immune cells on FFPE specimens through RNA

168 negative breast cancer (TNBC) with different intratumoral immune contexture, we demonstrate that a co

169 Solid tumors with low levels of intratumoral immune infiltration have inferior outcomes.

170 atory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing on

171 unique stromal properties, and dysfunctional intratumoral immune infiltration.

172 quences of persistent ER stress responses in intratumoral immune populations.

173 aken together, these results indicate robust intratumoral immune remodeling and a window of tumor-res

174 enhanced tumorigenesis through induction of intratumoral immunosuppression.

175 aling responsiveness as a key determinant of intratumoral immunosuppressive potential and clinical ou

176 d T helper type 2 (T(H)2) cytokines reflects intratumoral immunosuppressive potential, and predicts f

177 erived IL1 signaling in tumor stroma enabled intratumoral infiltration and activation of CD8(+) cytot

178 onment revealed that AA strikingly increased intratumoral infiltration of CD8+ T cells and macrophage

179 on the tumour cell surface, promoting robust intratumoral infiltration of cytotoxic T cells.

180 The combination treatment markedly enhanced intratumoral infiltration of macrophages and CD8+ T lymp

181 100) can decrease regulatory T (T(reg))-cell intratumoral infiltration.

182 arget for local immunostimulation, promoting intratumoral inflammation, and facilitating antitumor T

183 Intratumoral injection of ferumoxytol combined with AMF

184 No significant effect was observed after intratumoral injection of fumarate or PBS.

185 Intratumoral injection of HD/Se/ICG gel with NIR laser i

186 Intratumoral injection of recombinant EDN significantly

187 Intratumoral injection of the CART-mRNA complexes result

188 Notably, intratumoral injection of this cBiTE-expressing adenovir

189 Importantly, the intratumoral injection with the oncolytic virus overcome

190 Given that viral immunotherapy commonly uses intratumoral injection, prolonging the duration of thera

191 Whereas previous studies involved intratumoral injection, we report here an inhalable nano

192 actors that can affect tumor retention after intratumoral injection.

193 Intratumoral injections in human glioma xenografts revea

194 e melanoma model to evaluate the efficacy of intratumoral injections of recombinant NDVs engineered t

195 We treated a mouse model of melanoma with intratumoral injections of Toll-like receptor 1/2 (TLR1/

196 Our previous work revealed that intratumoral injections of wild-type murine CMV (MCMV) i

197 velopment of 1 for brain cancer treatment by intratumoral injections.

198 rmal or periareolar) or deep (peritumoral or intratumoral) injections were performed.

199 Combining intratumoral ISFIs with TUS may be beneficial for addres

200 The immunologic and therapeutic effects of intratumoral (IT) delivery of a novel virus-like particl

201 within lung adenocarcinoma that may underlie intratumoral lineage heterogeneity, metastasis, and acqu

202 ion of the spontaneous necrosis, and for the intratumoral localization of the immune infiltrate.

203 ing and barrier were associated with reduced intratumoral lymphocyte distribution and poor overall su

204 mbination with T cell clonal dominance among intratumoral lymphocytes prior to treatment or among per

205 via direct actions on TAM RTKs expressed on intratumoral macrophages and dendritic cells, leading to

206 tumor-infiltrating leukocytes, M1-polarized intratumoral macrophages, and activation of natural kill

207 ificantly reduced tumor growth and increased intratumoral macrophages.

208 hin the TME in vivo as well as a decrease in intratumoral MDSC and regulatory T cell (Treg).

209 easurements of cultured cells and by imaging intratumoral metabolic heterogeneity in specimens from p

210 nd demonstrated significant intertumoral and intratumoral metabolic heterogeneity, where lactate labe

211 w direct visualization and quantification of intratumoral metabolic heterogeneity, yet the throughput

212 should enable the faster characterization of intratumoral metabolic heterogeneity.

213 Additionally, intratumoral metalloinsertor administration resulted in

214 Furthermore, the discovery of an intratumoral microbiome and the elucidation of host-micr

215 r it is also has a physiological role in the intratumoral microenvironment and cancer drug resistance

216 Intratumoral microvessel density was studied using CD31

217 taxel delivery to cancer cells by decreasing intratumoral microvessel leakiness.

218 produce retinoic acid (RA), which polarizes intratumoral monocyte differentiation toward TAMs and aw

219 el of GIST and human specimens, we show that intratumoral murine CD103(+)CD11b(-) dendritic cells (DC

220 L8 is primarily expressed in circulating and intratumoral myeloid cells and that high IL8 expression

221 inase (CaMKK2) to be highly expressed within intratumoral myeloid cells in mouse models of breast can

222 T cells with the tumor but also impacts the intratumoral myeloid compartment.

223 ccine therapy did not significantly modulate intratumoral myeloid-derived suppressor cells quantitati

224 Intratumoral myeloid-derived suppressor cells were decre

225 We also tested intratumoral MYXV delivery and observed immune cell infi

226 We propose here a new approach to achieve intratumoral near-infrared (NIR) two-photon photodynamic

227 t on carcinoma cells, this led to widespread intratumoral necrosis and reduced tumor volume.

228 analysis of primary tumors revealed enhanced intratumoral necrosis upon silencing of tumor cell Angpt

229 High intratumoral nerve density correlates with poor prognosi

230 d that LIF titers positively correlated with intratumoral nerve density.

231 eptors LIFR and gp130 were expressed only in intratumoral nerves.

232 levated consumption of glutamine can lead to intratumoral nutrient depletion, causing metabolic stres

233 nst both tumor and viral antigens as well as intratumoral oHSV gene expression are important in oHSV-

234 Intratumoral parasympathetic nerves may have a dichotomo

235 MCMV reactivation was observed in intratumoral perivascular pericytes and tumor cells in m

236 ma, poorly-permeable blood vessels limit the intratumoral permeation and penetration of chemo or nano

237 Greater intratumoral presence of nanoformulated CCL21, compared

238 Early (<=3 days) intratumoral presentation of CAR T cells post-treatment

239 In this study, peritumoral and intratumoral radiomics was used to identify a vulnerable

240 ined therapy provoked brisk infiltration and intratumoral redistribution of cytotoxic CD8(+) T cells

241 ificant change in tumor hypoxia, with a mean intratumoral reduction in (18)F-flortanidazole tumor-to-

242 In conclusion, we found that intratumoral regions and ALNs(-) of TNBC contained highe

243 squalene-based adjuvanted vaccine maintains intratumoral regulatory B cells and fails to improve ant

244 r in combination with radiation (RT) reduced intratumoral regulatory T cells (Tregs) and increased ac

245 stically significant negative correlation of intratumoral remodeling with metastatic burden, while th

246 studies highlighted the polyclonal nature of intratumoral resistance mechanisms in some cases.

247 raint has left gaps in how radiation impacts intratumoral responses and whether tumor-resident T cell

248 Increased (68)Ga-PSMA-11 tracer uptake and intratumoral retention correlate with PSMA expression in

249 ariate analysis found that histologic grade, intratumoral S100 dendritic cells, and CD8 T lymphocytes

250 coma tumors showed that more than 80% of the intratumoral signal came from accumulation of [18F]F-Ara

251 icrodose (11)C-sorafenib PET did not predict intratumoral sorafenib concentrations after therapeutic

252 assigned to FOLFOX or IT, stratified by the intratumoral statuses of ERCC1 low (< 1.7) or high (>= 1

253 In vivo, we found higher levels of intratumoral stroma remodeling, determined by fibronecti

254 EMT-related genes are highly correlated with intratumoral stromal cell abundance and identify a speci

255 expression continuum driven by a mixture of intratumoral subpopulations, which was confirmed by sing

256 Human SCLC exhibits intratumoral subtype heterogeneity, suggesting that this

257 environment (TME) and cooperatively promoted intratumoral T cell exhaustion by modulating several inh

258 Poor intratumoral T cell infiltration and activation are majo

259 ation of vaccine and IDO1 inhibitor enhanced intratumoral T cell infiltration and function, but addin

260 oaches, we show that Gal1 blockade increases intratumoral T cell infiltration, leading to a better re

261 prime the tumor microenvironment by inducing intratumoral T cell infiltration.

262 f tumor, viral and self-immunopeptidomes and intratumoral T cell receptor clonality.

263 forced expression of ACADVL enabled enhanced intratumoral T cell survival and persistence in an engin

264 uppressive microenvironments, and inadequate intratumoral T cell trafficking and persistence.

265 Irradiated intratumoral T cells can mediate tumor control without n

266 unomodulation (ISIM) reshapes repertoires of intratumoral T cells, overcomes acquired resistance to a

267 ons suggest a novel "nonimmune" modality for intratumoral T reg and effector T cells in promoting tum

268 o evaluate the immunosuppressive activity of intratumoral T(R)(eg) cells; they may also allow tempora

269 ed tumor growth accompanied by a decrease in intratumoral T(reg) cells and enhancement of antitumor a

270 The origin of intratumoral T(reg) cells and their relationship with pe

271 idating approaches that specifically disrupt intratumoral T(reg) cells is direly needed for cancer im

272 ertoires further support the hypothesis that intratumoral T(reg) cells may originate primarily from p

273 onstrate that TRX518 reduces circulating and intratumoral T(reg) cells to similar extents, providing

274 Intratumoral T(reg) cells were decreased, and conversion

275 ip between peripheral blood T(reg) cells and intratumoral T(reg) cells, and highlight cytokine signal

276 t orchestrates the survival and functions of intratumoral T(reg) cells, and the therapeutic potential

277 reg) II cells) are phenotypically closest to intratumoral T(reg) cells, including in their expression

278 itical determinant to overcome mechanisms of intratumoral T-cell exclusion.

279 co-opted IL-8 release from tumors to enhance intratumoral T-cell trafficking through a CAR design for

280 r of T cell reprogramming and contributes to intratumoral Tcell radio-resistance.

281 This transcriptional program also increased intratumoral Tcf1(+) stem-like CD8(+) T cells and altere

282 tivating antigen-presenting cells, enhancing intratumoral Tcf1(+) stem-like CD8(+) T cells, and incre

283 Temporal changes in intratumoral TCR repertoire revealed expansion of T cell

284 We also review approved and clinical-stage intratumoral therapies and consider how the molecular an

285 ention and limit systemic exposure of potent intratumoral therapies.

286 emokine ligand 21 (CCL21) is effective as an intratumoral therapy able to slow the growth of cancers.

287 ze and charge) of these therapies influences intratumoral transport (e.g. tumor retention and cellula

288 ole than blood retention in the delivery and intratumoral transport of DOX, of which tumor accumulati

289 ion of CCL21 as a means to provide prolonged intratumoral treatment.

290 ntrolled system to interrogate the impact of intratumoral Treg cells on the TME.

291 Mechanistically, intratumoral Treg depletion is mediated by CD8(+) Teff-a

292 Similar trends of intratumoral Treg dynamics are observed in a small cohor

293 red mouse models, the WDR4/PML axis elevates intratumoral Tregs and M2-like macrophages and reduces C

294 his interaction-dependent labeling approach, intratumoral TSA-reactive CD4(+), CD8(+) T cells, and TS

295 The intratumoral TSL and dox distribution were analyzed by s

296 ded, in which the prognostic significance of intratumoral tumor infiltrating lymphocytes, as well as

297 application in cancer patients revealed high intratumoral uptake of both radiotracers already 10 min

298 Importantly, intratumoral vaccination also provides protection agains

299 rescence, however, was heterogenous owing to intratumoral variations in cellularity and necrosis.

300 t HPV-positive OPSCC patients have increased intratumoral Zn levels and AZGP1 expression, we identify